Natural history of pulmonary hemodynamics in primary pulmonary hypertension
References (25)
- et al.
Primary pulmonary hypertension
Am J Med
(1970) - et al.
Chest roentgenograms in primary pulmonary hypertension
Chest
(1979) - et al.
Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension
Am J Med
(1984) - et al.
Isoproterenol as a potential pulmonary vasodilator in primary pulmonary hypertension
Am J Cardiol
(1978) - et al.
Reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: guideline for determining a pulmonary vasodilator response
Am Heart J
(1983) - et al.
Vasodilator therapy for primary pulmonary hypertension
Primary pulmonary hypertension: a fatality during pulmonary angiography
Chest
(1973)Complications of angiography in primary pulmonary hypertension
Chest
(1974)Primary pulmonary hypertension: report of six cases and review of literature
Ann Intern Med
(1958)Primary pulmonary hypertension: a review and report of two cases
Asian Med J
(1974)
Report on a WHO meeting: primary pulmonary hypertension
Cited by (41)
Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: A systematic review of the literature
2010, Respiratory MedicineCitation Excerpt :Four other studies were identified that did not find an association between CO and mortality.22–25 For RVEDP, only 3 studies were identified that supported this parameter as a prognostic factor for mortality in IPAH20,26 (Ref.15,18,38) (Table 7). However two of these (Rozkovec et al.20 and Kanemoto et al.26) also reported the absence of an association depending on the type of analysis performed or the definition of survival that was used.
End Points and Clinical Trial Design in Pulmonary Arterial Hypertension
2009, Journal of the American College of CardiologyPrognostic impact of pulmonary arterial hypertension: A population-based analysis
2008, International Journal of CardiologyCitation Excerpt :Pulmonary arterial hypertension (PAH) is a rare but seemingly deadly condition of varying underlying aetiologies that result in an elevated mean pulmonary arterial pressure of > 25 mm Hg at rest, or 30 mm Hg with exercise and subsequent right heart failure [1]. Insidious in nature, PAH is often diagnosed long after pathological remodelling of all three layers of small pulmonary arteries causing vascular obstruction and raised pulmonary vascular resistance causing progressive right ventricular failure (the underlying reason for often unexplained dyspnoea equivalent to New York Heart Association Class II–IV symptoms) and a premature death [1]. PAH has attracted increasing interest with the combination of: a) the emergence of more effective therapies, b) greater efforts to standardise its detection and management and, finally, c) the introduction of a World Health Organisation sponsored classification system to better characterise the heterogeneous forms of pulmonary hypertension [2,3].
Noninvasive Assessment of Pulmonary Vascular Resistance Using Doppler Tissue Imaging of the Tricuspid Annulus
2007, Journal of the American Society of EchocardiographyCitation Excerpt :In the future, tricuspid DTI may be a useful adjunctive measure of PVR in these patients. In patients with primary pulmonary hypertension, an elevated PVR is an independent predictor of mortality.3,14,15 Invasive measurements of PVR are often followed to measure the efficacy of epoprostenol therapy.16,17
Surrogate End Points in Pulmonary Arterial Hypertension: Assessing the Response to Therapy
2007, Clinics in Chest MedicineACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines.
2006, Journal of the American College of Cardiology